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OBJECTIVES: The purpose of this study was to evaluate the incidence of urinary tract infection (UTI) in patients
with cystitis symptoms who underwent pelvic radiation therapy and identify correlated predictive factors.
METHODS: A prospective cohort study was conducted of patients who met the following: primary pelvic cancer
treated with curative intent, older than 18 years old, and good performance status. The exclusion criteria were
patients being treated for a UTI, using a urinary catheter, in dialysis or with cystostomy or nephrostomy, and
using antibiotics during treatment. Urinalysis and urine culture were collected before the beginning of
radiation therapy. Weekly evaluations of urinary symptoms were subsequently performed. In cases of new or
worsening symptoms, a questionnaire was applied, and new urine exams were collected. The UTI diagnosis was
defined by uroculture as bacterial growth greater than 104 CFU/mL.
RESULTS: From September 2014 to November 2015, 112 patients were sequentially recruited, and 72 (64%)
fulfilled the inclusion criteria. During follow-up, 24 (33%) patients had new urinary symptoms or worse
preexisting symptoms. A UTI was confirmed in the second urinary culture in only one (1.4%) patient.
CONCLUSIONS: The incidence of UTI was much lower than expected, suggesting that asymptomatic bacteriuria
develops symptoms due to radiotherapy. Due to the low rate of UTI, no predictive factor was identified.
KEYWORDS: Neoplasms; Cancer; Radiation Therapy; Pelvic Radiation Therapy; Urinary Tract Infection; Cystitis;
Incidence; Cohort Studies; Prospective Study; Controlled Study.
’ INTRODUCTION
The urinary bladder is frequently exposed, partially or
entirely, during radiation therapy for pelvic tumors. Due to
the effect of radiation on epithelial cells, acute functional
alterations, including increased urinary frequency, dysuria
and hematuria, can occur and may mimic the secondary
symptoms of urinary tract infection (UTI) (1).
The diagnosis of UTI is typically performed in the general
population based on signs and symptoms of cystitis, such as
dysuria, polyuria, urinary urgency, suprapubic pain, and
leukocyturia or bacteriuria in a biochemical analysis of
the urine sample, in the absence of vaginal symptoms in
women (2,3). When these findings are observed, empirical
antibiotic therapy is frequently initiated, especially in women,
while waiting for confirmation by urinary culture (3).
Although this approach has been established for women in
the community, it probably cannot be applied in individuals
undergoing pelvic radiation therapy. Usually, this population
has secondary cystitis symptoms resulting from the cancer
or its treatment (4-6). In addition, it has been estimated that
alterations observed on urinalysis, such as a high level of
leukocytes, a classic predictor of infectious cystitis, may
also be present in radiation cystitis (7). Approximately half of
patients with localized prostate cancer who underwent
radiation therapy with external beam irradiation present
urinary symptoms during treatment (5,6,8). However, the
estimated incidence of UTI in patients submitted to pelvic
radiation therapy varies from 6% to 45% (9-11).
Generally, the assessment of UTI incidence is considered a
secondary outcome; hence, no methodology is implemented
to exclude biases associated with this diagnosis (12). Thus,
there may be a low correlation between cystitis symptoms
and the presence of UTI in this population.
Currently, no available evidence is helpful in clinically
distinguishing infectious and radiation cystitis. The signs,DOI: 10.6061/clinics/2019/1388
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symptoms and biochemical urine analysis commonly used in
the general population to diagnose UTI probably are not
applicable in the population submitted to pelvic radiation
therapy. This could lead to excessive use of resources, which
could generate costs in propaedeutics and compromise
patient safety by leading to the excessive use of antibiotics.
The purposes of this study were to evaluate the incidence
of UTI among patients with symptoms of cystitis during
pelvic radiation therapy and identify possible correlated
predictive factors.
’ MATERIALS AND METHODS
A prospective cohort study was performed in patients
submitted to pelvic radiation therapy. The study was
approved by the respective Ethics in Research Committees
of the Hospital das Clínicas of the Faculty of Medicine of
the University of São Paulo (HC-FMUSP) and the Cancer
Institute of the State of São Paulo (ICESP). All patients who
agreed to participate in the study signed an informed
consent form.
The inclusion criteria were patients with prostate, rectal,
anal canal, uterine cervix, or endometrial cancer who under-
went pelvic radiation therapy with curative intent and had a
performance status less than or equal to 2 (Eastern Cooperative
Oncology Group - ECOG) (13). Patients using antibiotics or
urinary catheters in the 30 days prior to or during radiation
therapy and patients on dialysis or with cystostomy or
nephrostomy were excluded.
On the day of radiotherapy simulation, urine samples
were collected for urinalysis and urine cultures from the
eligible patients who agreed to participate in the study. During
treatment, urinary symptoms were assessed in weekly routine
evaluations with the nursing and medical staff. The specific
protocol of the study included an evaluation of the main
urinary symptoms related to the treatment, which were
graded according to Radiation Therapy Oncology Group (RTOG)
scores (14). Briefly, urinary symptoms, such as urinary
frequency, nocturia, dysuria, and urgency, were graded from
0 (zero) or none to 4 (worse). The patients were followed up
during treatment. In the event of the appearance of urinary
symptoms or worsening of preexisting symptoms, a ques-
tionnaire (Appendix) was applied to analyze possible risk
factors, and a second urinalysis and culture were performed.
The diagnosis of UTI was established when a urinary culture
showed bacterial growth greater than 104 CFU/mL (Gelose
chromIDs).
Statistical Analysis
Data in the literature show that the incidence of dysuria is
approximately 50% among patients submitted to pelvic
irradiation and that the rate of UTI varies from 6% to 45% in
this population (7-10). The sample size of this study was
calculated based on a 50% incidence of dysuria and a 10%
incidence of UTI. Considering that approximately 10 cases per
variable were needed for the multiple regression analysis, five
variables were pragmatically chosen for the analysis. Thus,
50 events of UTI would be necessary so that an initial sample
of 1,000 patients, which was calculated to contain at least
500 symptomatic patients was required.
Descriptive and frequency analyses were used to describe
and systematize all the data obtained during this study.
A multivariate regression analysis was planned to identify
factors that could predict the risk of infection and provide
early guidelines for clinical outcomes.
’ RESULTS
From September 2014 to November 2015, 112 patients
were recruited, and an interim analysis was then conducted.
Among the recruited patients, 29 were excluded because
they did not perform the first requested urinalysis type I
exam and uroculture, as were 11 patients who had a first
positive urinary culture. Thus, a total of 72 patients were
included and evaluated. Of these, 24 (33%) presented urinary
symptoms during irradiation, only one (4%) of whom had a
positive urinary culture.
Due to the lower than expected incidence of symptomatic
patients and especially the low incidence of UTI found in
the study, which was much lower than that used for the
sample calculation, patient recruitment was interrupted, and
the initially proposed regression analysis of UTI-predictive
factors was aborted.
The patients included in the study were mostly male (60%)
and older than 40 years old (98%). Prostate and rectal cancers
were more prevalent, at 36% and 31%, respectively. The
proportions of asymptomatic (51%) and symptomatic (49%)
patients were similar before treatment. Urinary urgency was
the most reported symptom (63%). Table 1 shows the patients’
characteristics.
During radiation therapy, only 24 (33%) patients presented
symptoms. The 48 patients who remained asymptomatic
were not submitted to any further urine exams. Patients
with primary anal canal cancer presented a higher rate of
symptoms (67%; 2/3 patients). Approximately one-third of
the patients with primary uterine cervix cancer, prostate
cancer, and rectal cancer also presented symptoms, while the
four patients with endometrial tumors did not present any
symptoms (Table 2).
Regarding the treatment technique, all patients received
external beam irradiation in the pelvis, and only 13 (18%)
patients with gynecological tumors underwent intracavitary
brachytherapy. The doses of external beam irradiation ranged
from 45 Gy to 78 Gy in fractions of 1.8 to 2 Gy/day.
Brachytherapy doses were 20 Gy across 4 fractions of 5 Gy
each on the vaginal vault surface (postoperative treatment) or
30 Gy across 4 fractions of 7.50 Gy each at point A for
definitive treatment.
Table 1 - Characteristics of the 72 included patients.
Characteristics Number of patients (%)
Sex Male 43 (60%)
Female 29 (40%)
Age o40 years old 2 (2%)
40-70 years old 41 (57%)
470 years old 29 (42%)
Primary tumor site Anal canal 3 (4%)
Cervix 16 (23%)
Endometrium 4 (6%)
Prostate 27 (36%)
Rectum 22 (31%)
Urinary symptoms
before radiotherapy
Asymptomatic 37 (51%)
Symptomatic 35 (49%)
Dysuria 5 (14%)
Urgency 22 (63%)
Nocturia (42x) 13 (37%)
Hematuria 0 (0%)
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Among the patients who presented symptoms, 29% were
treated with tridimensional conformal radiotherapy (3D-
CRT), 50% with intensity-modulated radiotherapy (IMRT),
and only three patients were submitted to brachytherapy
(Table 2). In 75% of the patients, the beginning or worsening
of the preexisting symptoms started after a median dose of
32.4 Gy (range, 15 to 45 Gy) of external beam radiotherapy.
The great majority of the patients (83%) presented dysuria as
the symptom that required the second urinary culture. No
hematuria or urinary urgency was reported (Table 2).
’ DISCUSSION
This study was proposed and designed to provide the
maximum information regarding urinary symptoms and
infection in the population submitted to pelvic radiation
therapy. The study design was established to control possible
biases related to the definite diagnosis of UTI through positive
urinary culture. The aim of this study was to provide guidance
for propaedeutics and therapeutics of these patients.
The estimated incidence of acute urinary symptoms in the
population submitted to pelvic radiation therapy is widely
variable. Values between 25% and 83% are usually described
(5,6,10,12,16). A 50% incidence was initially considered for
the sample calculation. In our study, 33% (24/72) of the
patients presented symptoms, a value that was lower than
expected. We attribute this relatively low incidence to the fact
that patients were treated with 3D-CRT or IMRT, which are
better than conventional bidimensional treatments at normal
tissue-sparing (6).
At the 14th month of recruitment, a low number (24) of
symptomatic patients was observed, and after an interim
analysis, enrollment was interrupted. Thus, it was not
possible to perform the evaluation of possible predictive
factors for UTI that was originally planned. Therefore, we
evaluated the data in a descriptive way.
The higher incidences of prostate and rectal cancers among
males and uterine cervix cancer among females in our
country (2) reflect the prevalence of these tumors in the study
population.
Paradoxically, patients submitted to IMRT, a technique
that allows better normal tissue sparing with less toxicity
than is caused by 3D-CRT (1,16), presented a higher incidence
of symptoms. However, in our daily routine, this technique is
reserved for cases of anal canal cancers, patients who need
higher doses for tumor control (such as those with prostate
cancer), and those with unfavorable anatomy for the
sparing of surrounding organs at risk (e.g., bladder cancer)
with 3D-CRT.
In our study, only patients with gynecological tumors
underwent intracavitary brachytherapy. It seems intuitive
that these patients would be more prone than other to develop
urinary symptoms due to the high dose of irradiation applied
to the region near the bladder as well as the need for a bladder
catheter during each procedure (7). However, compared to
other techniques, these patients had a lower incidence of
symptoms, at only 3/13 (23%). The other 10 patients under-
went treatment without urinary complaints.
In accordance with the average lifetime of mature cells of
the bladder and urethral epithelium (9), new symptoms or
the worsening of preexisting ones were observed in patients
who received a median dose of 32.4 Gy after approximately
2 to 3 weeks of radiation therapy.
Urinary symptoms resulting from radiation therapy are
usually reported on a generic genitourinary toxicity scale,
such as an RTOG score (14). Dysuria was the most reported
symptom and triggered a request for the second examination
in 83% of affected cases, resulting in an incidence of 28%
among treated patients (20/72).
At least two recent studies have prospectively assessed the
incidence of UTI among the population undergoing pelvic
radiation therapy. Both aimed to evaluate the effects of
cranberry ingestion in controlling cystitis symptoms and the
incidence of UTI. Bonneta et al. (10) evaluated 370 patients
who underwent pelvic radiation therapy and found a UTI
incidence of 24.2%. Cowan et al. (15) performed a randomized
trial with 128 patients who took a placebo or cranberry. The
incidence of UTI among this population was 44.1%. Although
the incidence of UTI was high in these studies, no urinary
evaluation was performed before treatment. The absence of a
urinalysis control before the beginning of treatment may have
contributed to the high incidence of UTI among the study
population as several of these patients could have been carriers
of asymptomatic bacteriuria.
Only two other studies have performed a prospective
evaluation of the population involving type I urinalysis and
urine culture in all patients prior to treatment. Bialas et al. (9)
evaluated 172 patients in 1989 and prospectively observed
that the prevalence of positive uroculture was 17% prior
to radiotherapy and 17% during treatment. In a 1994 study,
Prasad et al. (11) prospectively evaluated patients with
primary gynecological tumors. They found that the risk of
UTI was higher among those submitted to cystoscopy prior
to radiation therapy and bladder catheterization in intraca-
vitary brachytherapy. Weekly urinary cultures were per-
formed without symptom assessment, and 10% of the
patients presented with a positive urinary culture before the
beginning of treatment, while 23% presented with positive
results during radiation therapy.
In their study, Shuford et al. (7) evaluated the urine exams
of 134 women with primary pelvic tumors treated with
pelvic radiation therapy. The purpose was to identify urine
Table 2 - Characteristics of the 24 (33%) symptomatic patients
and their respective symptom incidences during radiation
therapy.
Characteristics Symptom
Incidence (%)
Primary tumor site Anal canal 2/3 (67%)
Cervix 5/16 (31%)
Endometrium 0/4 (0%)
Prostate 10/27 (37%)
Rectum 7/22 (32%)
Treatment technique 3D-CRT 16/56 (29%)
IMRT 8/16 (50%)
Brachytherapy 3/13 (23%)
Pelvic Radiation Dose at
symptom appearance/worsening
o5 Gy 0/24 (0%)
6-15 Gy 2/24 (8%)
16-25 Gy 6/24 (25%)
26-35 Gy 6/24 (25%)
36-45 Gy 6/24 (25%)
46-55 1/24 (4%)
56-65 Gy 2/24 (8%)
465 Gy 1/24 (4%)
Urinary symptoms Dysuria 20/24 (83%)
Urinary urgency 0/24 (0%)
Nocturia 4/24 (16%)
Hematuria 0/24 (0%)
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analysis parameters that could predict UTI with urinary
culture used as the gold standard. However, theirs was a
retrospective study without an assessment of urinary status
prior to the beginning of treatment. Therefore, their results
may contain the same biases found in previous studies
regarding patients with asymptomatic bacteriuria.
In our study, all 112 of the evaluated patients underwent
urinary culture prior to the beginning treatment, and 10%
were identified as already having a positive urinary culture,
a value close to those of the previous 2 studies that per-
formed this evaluation prior to treatment. We decided to
exclude these patients in advance because we sought to
evaluate the actual incidence of UTI during treatment.
When we compared the incidence of UTI during treatment
obtained in this study to those obtained in previous studies
that included a control urinary culture performed prior to
the beginning of radiation therapy, we found that ours was
much lower. While Bialas et al. and Prassad et al. reported
incidences of 17% and 23%, respectively, ours was only 4%
(one patient). This difference may be because the two pre-
vious studies performed weekly urinary culture exams in all
patients regardless of the presence or absence of symptoms.
We consider, therefore, that the 4% incidence of UTI
detected in our study is well below that found in the pre-
vious literature mainly due to two factors. The first factor is
that we performed urinary culture exams before radiation
therapy and excluded patients with positive results. The
second is that we investigated only patients with urinary
symptoms. Thus, we excluded patients with asymptomatic
bacteriuria and investigated only those who became suspi-
cious for UTI due to the presence of symptoms.
Based on these results, we conclude that the frequency of
UTI reported to date actually reflects the incidence of patients
with asymptomatic bacteriuria who developed secondary
symptoms due to radiation therapy and were erroneously
classified as having a UTI based on the classic criteria used for
patients in the community.
Our results are extremely important for clinical practice.
The low incidence of UTI found in our study should prompt
a discussion about the application of the clinical diagnostic
criteria for UTIs used in patients undergoing pelvic radiation
therapy. The frequency of false diagnoses appears to generate
excessive empirical treatments in this population.
To the best of our knowledge, this is the first prospectively
controlled study to analyze the real incidence of UTI among
the population treated with pelvic radiation therapy. The
very low incidence found in this study highlights the
importance of using the correct approach in these patients to
avoid excessive diagnoses, expenses related to propaedeutics
and the application of unnecessary empirical treatments in this
population, which can even lead to antimicrobial resistance.
Our results should not only stimulate efforts aimed at avoid-
ing empirical treatments, such as antibiotics, in this population
but also demonstrate that it is safe to wait for the results of
uroculture analysis before selecting the appropriate antibiotic
therapy in patients without neutropenia and fever.
’ AUTHOR CONTRIBUTIONS
Xavier VF was responsible for the study conceptualization, data curation,
formal analysis, investigation, methodology and project administration.
Gabrielli FCG was responsible for for the study conceptualization,
methodology and formal analysis. Ibrahim KY was responsible for the
study conceptualization, methodology and forma analysis. Gomes MVS
was responsible for the study conceptualization, data curation and
investigation. Guimarães RGR was responsible for the study conceptualiza-
tion, data curation and investigation. Abdala E was responsible for the
study conceptualization and methodology. Carvalho HA was responsible
for the study conceptualization, data curation, formal analysis, investiga-
tion, methodology and project administration.
’ REFERENCES
1. Viswanathan AN, Yorke ED, Marks LB, Eifel PJ, Shipley WU. Radiation
dose–volume effects of the urinary bladder. Int J Radiat Oncol Biol
Phys. 2010;76(3 Suppl): S116-22. https://doi.org/10.1016/j.ijrobp.2009.
02.090
2. Bent S, Nallamothu BK, Simel DL, Fihn SD, Saint S. Does this woman
have an acute uncomplicated urinary tract infection? JAMA. 2002;287(20):
2701-10. https://doi.org/10.1001/jama.287.20.2701
3. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al.
International clinical practice guidelines for the treatment of acute
uncomplicated cystitis and pyelonephritis in women: A 2010 update by
the Infectious Diseases Society of America and the European Society for
Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103-20.
https://doi.org/10.1093/cid/ciq257
4. Wallace DM, Raghavan D, Kelly KA, Sandeman TF, Conn IG, Teriana N,
et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transi-
tional cell carcinoma of the bladder. Br J Urol. 1991;67(6):608-15. https://
doi.org/10.1111/j.1464-410X.1991.tb15225.x
5. Crook J, Esche B, Futter N. Effect of pelvic radiotherapy for prostate
cancer on bowel, bladder, and sexual function: the patient’s perspec-
tive. Urology. 1996;47(3):387-94. https://doi.org/10.1016/S0090-4295(99)
80458-0
6. Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, Tait D, et al.
Comparison of radiation side-effects of conformal and conventional
radiotherapy in prostate cancer: a randomised trial. Lancet. 1999;353
(9149):267-72. https://doi.org/10.1016/S0140-6736(98)05180-0
7. Shuford RA, Dulaney CR, Burnett OL 3rd, Byram KW, McDonald AM.
Evaluating the Role of Urinalysis for Suspected Cystitis in Women
Undergoing Pelvic Radiotherapy. Int J Gynecol Cancer. 2016. [Epub ahead
of print].
8. Peeters ST, Heemsbergen WD, van Putten WL, Slot A, Tabak H, Mens JW,
et al. Acute and late complications after radiotherapy for prostate cancer:
results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J
Radiat Oncol Biol Phys. 2005;61(4):1019-34. https://doi.org/10.1016/
j.ijrobp.2004.07.715
9. Bialas I, Bessell EM, Sokal M, Slack R. A prospective study of urinary tract
infection during pelvic radiotherapy. Radiother Oncol. 1989;16(4):305-9.
https://doi.org/10.1016/0167-8140(89)90043-1
10. Bonneta A, Di Pierro F. Enteric-coated, highly standardized cranberry
extract reduces risk of UTIs and urinary symptoms during radiotherapy
for prostate carcinoma. Cancer Manag Res. 2012;4:281-6. https://doi.org/
10.2147/CMAR.S35342
11. Prasad KN, Pradhan S, Datta NR. Urinary tract infection in patients
of gynecological malignancies undergoing external pelvic radiotherapy.
Gynecol Oncol. 1995;57(3):380-2. https://doi.org/10.1006/gyno.1995.
1158
12. Gordon L. Cranberry in radiotherapy: dispelling the myths. A review of
the literature. J Radiother Pract. 2014;13(1):98-105. https://doi.org/
10.1017/S1460396913000320
13. ECOG-ACRIN Cancer research Group. [cited Nov 24th, 2017]. Available
from: http://ecog-acrin.org/resources/ecog-performance-status.
14. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy
Oncology Group (RTOG) and the European Organization for Research
and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;
31(5):1341-6. https://doi.org/10.1016/0360-3016(95)00060-C
15. Cowan CC, Hutchison C, Cole T, Barryl SJ, Paul J, Reed NS, et al.
A randomised double-blind placebo-controlled trial to determine the
effect of cranberry juice on decreasing the incidence of urinary symptoms
and urinary tract infections in patients undergoing radiotherapy for
cancer of the bladder or cervix. Clin Oncol. 2012;24(2):e31-8. https://doi.
org/10.1016/j.clon.2011.05.009
16. Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, et al.
Incidence of late rectal and urinary toxicities after three-dimensional
conformal radiotherapy and intensity-modulated radiotherapy for loca-
lized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(4):1124-9.
https://doi.org/10.1016/j.ijrobp.2007.11.044
4
Urinary infection or radiation cystitis?
Xavier VF et al.
CLINICS 2019;74:e1388
’ APPENDIX
Clinical questionnaire
PATIENT IDENTIFICATION
NAME: AGE:
DATE:
RGHC: PACS:
SIMULATION TOMOGRAPHY
URINARY SYMPTOMS:
____Dysuria ____Urinary urgency ___Nocturia (____number) ___Hematuria
EXCLUSION CRITERIA? ____YES ___NO (if YES, specify)
____ USE OF ANTIBIOTICS IN THE PAST 30 DAYS ____ECOG p 2 ___PALLIATIVE
____ DIALYSIS ____CYTOSTOMY/NEFROSTOMY____URINARY CATHETERS
____ NOT JOIN ____ OTHERS: ______________________________
NURSE
SYMPTOM IDENTIFICATION (DATE)______/______/______
ANTIBIOTIC DURING TREATMENT? ___YES ___NO (if YES, exclude)
RISK FACTORS
FECAL INCONTINENCE? ____YES ___NO
DIAPER USE LAST WEEK ___YES ___ NO
UTI NUMBER IN THE LAST 12 MONTHS: __________
LAST UTI TREATED (HOW MANY MONTHS AGO)? _____
CHANGE IN URINE ASPECT IN THE LAST WEEK? ____YES ___NO
DO YOU THINK YOU HAVE A URINARY TRACT INFECTION? ____YES ____NO
URINARY TRACT SYMPTOMS (Acute Radiation Morbidity Scoring Criteria, RTOG)
______GRADE 1 (Does not require medication)
____Dysuria ____Urinary urgency ____Nocturia (require medication)
______GRADE 2 (requires medication)
____Dysuria ____Urinary urgency ____ Nocturia (2X greater than pretreatment)
______GRADE 3 (Opioid use for urinary symptoms, macroscopic hematuria, severe nocturia)
____Dysuria ____Urinary urgency ____ Nocturia (1/1 h) ___Hematuria
______GRADE 4 (Blood transfusion secondary to hematuria, urethral obstruction, necrosis/ulceration)
PHYSICIAN
PRIMARY TUMOR SITE: ___ PROSTATE___ CERVIX ___ ENDOMETRIUM ___ RECTAL ___ANAL ___Other: Which:______________________
CONCOMITANT CHEMOTHERAPY? ___YES ___NO
RT DOSE ON DATE OF SYMPTOMS: ________cGy ____Fx
PRESCRIBED DOSE: _________cGy ____Fx
BRACHYTHERAPY BEFORE SYMPTOMS? ___YES ___NO.
IF YES, HOW MANY?______
LEUKOCYTURIA: _______________ HEMATURIA:____________NITRITE:_____________
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